NRG-LU005

Closed to Accrual

Return to Protocol Table

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab

Principal Investigator

Kristin Higgins, MD

Co-Principal Investigator(s)

Helen Ross, MD

Status

Closed to Accrual

Date Opened To Accrual

May 28 2019

Date Closed to Accrual

December 31 2023

Disease Site

Lung [LU]

Small Cell

Phase

III

Developmental Therapeutics

Primary Objective

To compare overall survival (OS) for patients with LS-SCLC treated with chemoradiation +/- atezolizumab.

Patient Population

Patients with pathologically (histologically or cytologically) proven diagnosis of limited stage (Tx, T1-T4, N0-3, M0) small cell lung cancer (LS-SCLC) who have received one pre-registration cycle of platinum/etoposide chemotherapy prior to study entry.

Target Accrual

506

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.

Patient Study Webpage

To learn more about this study, visit the Patient Study Webpage.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.